MCID: SRT004
MIFTS: 48

Serotonin Syndrome

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Serotonin Syndrome

MalaCards integrated aliases for Serotonin Syndrome:

Name: Serotonin Syndrome 59 55 17
Malignant Carcinoid Syndrome 72
Serotonergic Syndrome 59
Serotonin Toxidrome 59
Serotonin Toxicity 59
Serotonin Storm 59

Characteristics:

Orphanet epidemiological data:

59
serotonin syndrome
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

MESH via Orphanet 45 D020230
UMLS via Orphanet 73 C0699828
Orphanet 59 ORPHA43116
UMLS 72 C0024586

Summaries for Serotonin Syndrome

MalaCards based summary : Serotonin Syndrome, also known as malignant carcinoid syndrome, is related to depression and fibromyalgia. An important gene associated with Serotonin Syndrome is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Peptide ligand-binding receptors and Serotonergic synapse. The drugs Nitric Oxide and Mannitol have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and heart, and related phenotypes are no effect and Decreased viability

Wikipedia : 75 Serotonin syndrome (SS) is a group of symptoms that may occur with the use of certain serotonergic... more...

Related Diseases for Serotonin Syndrome

Diseases related to Serotonin Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 245)
# Related Disease Score Top Affiliating Genes
1 depression 30.8 SLC6A4 MAOA HTR2A HTR1A
2 fibromyalgia 30.6 SLC6A4 HTR3A HTR2A
3 generalized anxiety disorder 30.1 SLC6A4 MAOA HTR3A HTR2A HTR1A
4 mental depression 30.1 SLC6A4 OXT MAOA HTR2A HTR1A CYP2D6
5 diarrhea 30.1 SST HTR3A GAST CYP3A4
6 endogenous depression 30.0 SLC6A4 MAOA HTR2A HTR1A
7 panic disorder 30.0 SLC6A4 MAOA HTR3A HTR2A HTR1A
8 post-traumatic stress disorder 29.9 SLC6A4 MAOB MAOA HTR2A
9 mood disorder 29.9 SLC6A4 MAOB MAOA HTR2A HTR1A
10 parkinson disease, late-onset 29.8 SLC6A4 MAOB MAOA HTR2A HTR1A CYP2D6
11 major depressive disorder 29.8 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
12 obsessive-compulsive disorder 29.7 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
13 migraine with or without aura 1 29.5 TAC1 SLC6A4 MAOA HTR3A HTR2A HTR1A
14 anorexia nervosa 29.1 SLC6A4 PYY OXT HTR2A GHRH
15 small cell cancer of the lung 29.0 SST GAST CHGA
16 attention deficit-hyperactivity disorder 29.0 SLC6A4 OXT MAOB MAOA HTR2A HTR1A
17 anxiety 28.7 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
18 constipation 28.4 TAC1 SST SLC6A4 PYY HTR3A GAST
19 carcinoid syndrome 28.0 SST PYY MEN1 IFNA2 HTR3A GHRH
20 schizoid personality disorder 10.7 HTR2A HTR1A
21 substance-induced psychosis 10.7 HTR2A HTR1A
22 hypoactive sexual desire disorder 10.7 HTR2A HTR1A
23 schizophrenia 5 10.6 HTR3A HTR2A HTR1A
24 avoidant personality disorder 10.6 SLC6A4 MAOA
25 rumination disorder 10.6 HTR3A HTR1A
26 phobic disorder 10.6 SLC6A4 MAOA HTR1A
27 psychosexual disorder 10.6 SLC6A4 HTR2A HTR1A
28 premature ejaculation 10.6 SLC6A4 HTR3A HTR1A
29 dependent personality disorder 10.5 MAOB MAOA CYP3A4
30 dysthymic disorder 10.5 SLC6A4 MAOA HTR2A
31 agoraphobia 10.5 SLC6A4 MAOA HTR1A
32 periodic limb movement disorder 10.5 SLC6A4 HTR2A HTR1A
33 paranoid schizophrenia 10.5 SLC6A4 MAOA HTR2A
34 tremor 10.5
35 sexual disorder 10.5 SLC6A4 OXT HTR1A
36 antisocial personality disorder 10.5 SLC6A4 MAOB MAOA
37 bipolar i disorder 10.5 SLC6A4 HTR2A HTR1A
38 paraphilia disorder 10.5 OXT MAOB MAOA
39 substance abuse 10.5 SLC6A4 MAOA CYP2D6
40 tobacco addiction 10.5 SLC6A4 MAOA HTR2A
41 gastrointestinal neuroendocrine tumor 10.5 SST CHGA
42 hemangioma of liver 10.5 IFNA2 CYP3A4
43 substance dependence 10.5 SLC6A4 MAOA CYP2D6
44 postpartum depression 10.5 SLC6A4 OXT MAOA
45 myoclonus 10.5
46 social phobia 10.4 SLC6A4 MAOA HTR3A HTR1A
47 neuroleptic malignant syndrome 10.4
48 intestinal neuroendocrine benign tumor 10.4 SSTR1 MEN1
49 borderline personality disorder 10.4 SLC6A4 MAOA HTR2A HTR1A
50 pituitary carcinoma 10.4 SST CHGA

Comorbidity relations with Serotonin Syndrome via Phenotypic Disease Network (PDN):


Intestinal Obstruction

Graphical network of the top 20 diseases related to Serotonin Syndrome:



Diseases related to Serotonin Syndrome

Symptoms & Phenotypes for Serotonin Syndrome

GenomeRNAi Phenotypes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 CGB3 CHGA CYP2D6 CYP3A4 GAST GHRH
2 Decreased viability GR00381-A-1 9.61 HTR1A HTR3A SLC6A4
3 Decreased viability GR00381-A-3 9.61 HTR1A HTR3A SLC6A4
4 Decreased viability GR00402-S-2 9.61 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Serotonin Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 HTR1A HTR2A HTR3A MAOA MAOB OXT
2 endocrine/exocrine gland MP:0005379 9.81 CHGA GAST GHRH HTR2A HTR3A MEN1
3 homeostasis/metabolism MP:0005376 9.8 CHGA GAST GHRH HTR1A HTR3A MAOA
4 nervous system MP:0003631 9.44 CHGA GHRH HTR1A HTR3A MAOA MAOB

Drugs & Therapeutics for Serotonin Syndrome

Drugs for Serotonin Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Prilocaine Approved Phase 4 721-50-6 4906
6
Rasagiline Approved Phase 4 136236-51-6 3052776
7
Tapentadol Approved Phase 4 175591-23-8 9838022
8
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
12
Sodium citrate Approved, Investigational Phase 4 68-04-2
13
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
14
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
15
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
16 Pharmaceutical Solutions Phase 4
17 Natriuretic Agents Phase 4
18 diuretics Phase 4
19 Epinephryl borate Phase 4
20 Neuroprotective Agents Phase 4
21 Monoamine Oxidase Inhibitors Phase 4
22 Psychotropic Drugs Phase 4
23 Hormones Phase 4
24 Calcium, Dietary Phase 4
25 Tranquilizing Agents Phase 4
26 Anti-Anxiety Agents Phase 4
27 Neurotransmitter Uptake Inhibitors Phase 4
28 Adrenergic Agents Phase 4
29 Anticonvulsants Phase 4
30 calcium channel blockers Phase 4
31 Neurotransmitter Agents Phase 4
32 Dopamine agonists Phase 4
33 Protective Agents Phase 4
34 Dopamine Agents Phase 4
35 Peripheral Nervous System Agents Phase 4
36 Antioxidants Phase 4
37 S 20098 Phase 4
38 Antiparkinson Agents Phase 4
39 Hypnotics and Sedatives Phase 4
40 Central Nervous System Depressants Phase 4
41 Analgesics Phase 4
42 Narcotics Phase 4
43 Analgesics, Opioid Phase 4
44 Citrate Phase 4
45 Adjuvants, Anesthesia Phase 4
46 Anesthetics Phase 4
47 Anesthetics, General Phase 4
48 Excitatory Amino Acid Antagonists Phase 4
49 Anesthetics, Dissociative Phase 4
50 Anesthetics, Intravenous Phase 4

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
2 Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study Recruiting NCT03843944 Phase 4 Safinamide
3 Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Unilateral Total Knee Arthroplasty- A Randomised, Double Blind, Active Control, Clinical Trial Recruiting NCT03604354 Phase 4 Tapentadol 100 MG Oral Tablet;Pregabalin 150mg
4 A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease Not yet recruiting NCT03977441 Phase 4 Agomelatine or PIacebo
5 A Combination Study With Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain in the Emergency Department Not yet recruiting NCT03959852 Phase 4 Fentanyl;Ketamine
6 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
7 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) Completed NCT02026063 Phase 3 Telotristat etiprate tablets (250 mg)
8 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
9 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
10 A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
11 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
12 Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
13 Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Not yet recruiting NCT04065165 Phase 3 Telotristat Ethyl;Lanreotide
14 A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
15 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
16 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
17 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
18 A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid Completed NCT00002470 Phase 2 fluorouracil
19 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
20 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
21 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
22 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
23 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
24 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
25 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
26 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
27 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
28 Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
29 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
30 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
31 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
32 Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET Recruiting NCT03453489 Phase 2 Telotristat Etiprate
33 A Phase 2 Study Evaluating a Proprietary Amino Acid Based Medical Food (Enterade®) in Patients With Quality of Life Limiting Diarrhea Due to Carcinoid Syndrome and Other Neuroendocrine Tumors (NET). Recruiting NCT03722511 Phase 2
34 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
35 Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib;Pazopanib Hydrochloride
36 Phase II Randomised Trial to Assess Progression of Carcinoid Heart Disease in Patients Treated With Lutathera Therapy Compared to Best Supportive Care. Not yet recruiting NCT04039516 Phase 2 Lutathera
37 Open Label Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome Terminated NCT00884715 Phase 1, Phase 2 Octreotide
38 Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Terminated NCT01018953 Phase 2 BIM 23A760
39 Phase II Study of Above-Label Octreotide-LAR in Patients With Insufficiently Controlled Carcinoid Syndrome Terminated NCT01886287 Phase 2 Octreotide LAR
40 Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
41 A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting Terminated NCT00903396 Phase 2 palonosetron hydrochloride
42 Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome Withdrawn NCT01172717 Phase 2 Panitumumab
43 Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
44 A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects Completed NCT01932528 Phase 1 500 mg [14C]-LX1606
45 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
46 A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumor Completed NCT01548482 Phase 1 Temsirolimus
47 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
48 Phase I Study to Evaluate the Combination Chemotherapy Regimen of Oxaliplatin Plus Irinotecan in Previously Treated Patients With Metastatic Gastrointestinal Cancer Completed NCT00003427 Phase 1 irinotecan hydrochloride;oxaliplatin
49 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
50 A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium

Search NIH Clinical Center for Serotonin Syndrome

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Interferon Alfa-2b

Genetic Tests for Serotonin Syndrome

Anatomical Context for Serotonin Syndrome

MalaCards organs/tissues related to Serotonin Syndrome:

41
Brain, Bone, Heart, Liver, Small Intestine, Breast, Colon

Publications for Serotonin Syndrome

Articles related to Serotonin Syndrome:

(show top 50) (show all 1249)
# Title Authors PMID Year
1
Is tapentadol an advance on tramadol? 9 38
20092221 2009
2
[Serotonin syndrome associated with linezolid use: a case report]. 9 38
20013432 2009
3
Serotonin syndrome: a complex but easily avoidable condition. 9 38
18433663 2008
4
5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome. 9 38
15743927 2005
5
The serotonin syndrome. 9 38
15635814 2004
6
Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. 9 38
11889332 2002
7
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. 9 38
10090793 1999
8
Treatment of the serotonin syndrome with cyproheptadine. 9 38
9696181 1998
9
Serotonin syndrome and drug combinations: focus on MAOI and RIMA. 9 38
9224903 1997
10
Serotonin syndrome complicating migraine pharmacotherapy. 9 38
8869767 1996
11
[Serotonin syndrome in acute poisoning with antidepressive agents]. 9 38
9033760 1996
12
Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: myoclonus and other serotonergic behaviors. 9 38
1387164 1992
13
Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease. 38
31424178 2019
14
Oral fenugreek seed consumption and serotonin syndrome. 38
31379190 2019
15
Differential role of dose and environment in initiating and intensifying neurotoxicity caused by MDMA in rats. 38
31383036 2019
16
Behavioral effects of citalopram, tramadol, and binary mixture in zebrafish (Danio rerio) larvae. 38
31425864 2019
17
Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin-an Intracerebral Microdialysis Study in Sprague-Dawley Rats. 38
31010933 2019
18
Focal seizure as a manifestation of serotonin syndrome: case report. 38
31404205 2019
19
Takotsubo Cardiomyopathy: Medical and Psychiatric Aspects. Role of Psychotropic Medications in the Treatment of Adults with "Broken Heart" Syndrome. 38
31423403 2019
20
Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations. 38
31291209 2019
21
Fatal overdose with a combination of SNRIs venlafaxine and duloxetine. 38
30796754 2019
22
Citalopram overdose and severe serotonin syndrome in an intermediate metabolizing patient. 38
31257122 2019
23
A Case of Serotonin Syndrome Caused by the Concomitant Utilization of Methylene Blue and Venlafaxine in an Oncological Patient. 38
31232145 2019
24
Multivisceral Failure in a Context of Serotonin Syndrome Induced by MDMA: The Investigation of a Unique and Nationwide Network. 38
31188157 2019
25
An atypical case of serotonin syndrome with normal dose of selective serotonin inhibitors: A case report. 38
31083217 2019
26
Serotonin Syndrome After an Alcohol Intake in a Patient Treated With Escitalopram and Clomipramine. 38
30844852 2019
27
The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice. 38
31075831 2019
28
Clinically Significant Drug-Drug Interactions Involving Medications Used for Symptom Control in Patients With Advanced Malignant Disease: A Systematic Review. 38
30776538 2019
29
A Mixed Presentation of Serotonin Syndrome Versus Neuroleptic Malignant Syndrome in a 12-Year-Old Boy. 38
30964850 2019
30
A Rare Overlap of Serotonin Syndrome and Status Epilepticus Confirmed on Electroencephalogram. 38
31328059 2019
31
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. 38
29368539 2019
32
A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy. 38
31030620 2019
33
ISMP Adverse Drug Reactions: Longitudinal Thumbnail Fissures Due to Erlotinib Priapism Associated With the Use of ExtenZe Blindness From a Nevirapine-Based HAART Regimen Hyperprolactinemia and Galactorrhea Due to Aripiprazole Trypophobia Associated With Gabapentin Coadministered Linezolid and Methadone Cause Serotonin Syndrome. 38
30923400 2019
34
An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California Poison Control System. 38
30650197 2019
35
Non-Fatal Intoxication with a High Dose of Citalopram in a Suicidal 14-Year-Old Girl. 38
30185094 2019
36
Life-Threatening Serotonin Syndrome Due to Methylene Blue-Citalopram Interaction. 38
30855287 2019
37
Takotsubo cardiomyopathy associated with serotonin syndrome in a patient with stroke: A case report. 38
30921235 2019
38
Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions. 38
30832967 2019
39
Serotonin syndrome unmasking thyrotoxicosis. 38
30850570 2019
40
Serotonin Syndrome Following Tramadol and Gabapentin Use After Spine Surgery. 38
30898741 2019
41
Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action. 38
30667206 2019
42
Movement Disorders Emergencies. 38
30743298 2019
43
[The serotonin syndrome: An updated literature review]. 38
30243558 2019
44
[Serotin syndrome; literature overview and Lareb pharmacovigilance reports]. 38
30816647 2019
45
5-HT1A receptor agonist 8-OH-DPAT induces serotonergic behaviors in mice via interaction between PKCδ and p47phox. 38
30366073 2019
46
Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques. 38
30886699 2019
47
Neuromuscular abnormalities in serotonin syndrome may be mistaken as seizure: A report and literature review. 38
30860132 2019
48
Serotonin Syndrome and Hippocampal Infarction. 38
30420109 2019
49
Serotonin and Norepinephrine Reuptake Inhibitors. 38
30838456 2019
50
Serotonin Syndrome in Obstetrics: A Case Report and Review of Management. 38
29901770 2019

Variations for Serotonin Syndrome

Expression for Serotonin Syndrome

Search GEO for disease gene expression data for Serotonin Syndrome.

Pathways for Serotonin Syndrome

GO Terms for Serotonin Syndrome

Cellular components related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TAC1 SST PYY OXT IFNA2 GHRH
2 integral component of presynaptic membrane GO:0099056 9.43 SLC6A4 HTR3A HTR2A
3 integral component of postsynaptic membrane GO:0099055 9.33 SLC6A4 HTR3A HTR2A
4 extracellular region GO:0005576 9.32 TAC1 SST PYY OXT NOTCH1 IFNA2

Biological processes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.92 SST SLC6A4 MAOB HTR2A
2 neuropeptide signaling pathway GO:0007218 9.78 TAC1 SSTR1 PYY
3 memory GO:0007613 9.75 SLC6A4 OXT HTR2A
4 chemical synaptic transmission GO:0007268 9.72 TAC1 SST HTR3A HTR2A HTR1A
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.7 SSTR1 HTR2A HTR1A
6 cell-cell signaling GO:0007267 9.65 TAC1 SST IFNA2 GHRH CGB3
7 vasoconstriction GO:0042310 9.62 SLC6A4 HTR1A
8 negative regulation of cell-substrate adhesion GO:0010812 9.61 NOTCH1 MEN1
9 positive regulation of cytosolic calcium ion concentration GO:0007204 9.61 TAC1 OXT HTR2A
10 G protein-coupled receptor signaling pathway GO:0007186 9.61 TAC1 SSTR1 SST PYY OXT HTR2A
11 positive regulation of renal sodium excretion GO:0035815 9.6 TAC1 OXT
12 positive regulation of ossification GO:0045778 9.59 TAC1 OXT
13 sleep GO:0030431 9.58 OXT HTR2A
14 neurotransmitter catabolic process GO:0042135 9.57 MAOB MAOA
15 oxidative demethylation GO:0070989 9.56 CYP3A4 CYP2D6
16 behavior GO:0007610 9.55 HTR2A HTR1A
17 dopamine catabolic process GO:0042420 9.54 MAOB MAOA
18 response to steroid hormone GO:0048545 9.54 SST OXT MAOB
19 heterocycle metabolic process GO:0046483 9.51 CYP3A4 CYP2D6
20 monoterpenoid metabolic process GO:0016098 9.49 CYP3A4 CYP2D6
21 drug catabolic process GO:0042737 9.48 CYP3A4 CYP2D6
22 sperm ejaculation GO:0042713 9.46 SLC6A4 OXT
23 alkaloid catabolic process GO:0009822 9.4 CYP3A4 CYP2D6
24 response to food GO:0032094 9.33 OXT GHRH GAST
25 serotonin receptor signaling pathway GO:0007210 8.8 HTR3A HTR2A HTR1A

Molecular functions related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.35 SST PYY OXT GAST CGB3
2 neuropeptide hormone activity GO:0005184 9.33 PYY OXT GHRH
3 primary amine oxidase activity GO:0008131 9.26 MAOB MAOA
4 serotonin binding GO:0051378 8.92 SLC6A4 HTR3A HTR2A HTR1A

Sources for Serotonin Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....